Breast, Ovarian Cancer Drug Olaparib Targets Enzymes in Tumor Cells

Breast, Ovarian Cancer Drug Olaparib Targets Enzymes in Tumor Cells
breast cancerA recent study found that olaparib, a drug approved for breast and ovarian cancer patients with inherited mutations in the genes BRCA1 or BRCA2, targets an enzyme called polymerase q (POLQ) present in tumor cells. The study entitled “Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair” was published in Nature by Dana-Farber Cancer Institute researchers. Dr. Alan D’Andrea said in a news release that approximately 10 to 15% of ovarian cancers occur in women who carry inherited mutations in BRCA1 or BRCA2 genes. Olaparib is a chemotherapeutic agent belonging to the PARP (poly ADP-ribose polymerase) inhibitor class of drugs that targets a specific mechanism by which cells repair double-strand DNA. This drugs targets tumor cells that carry mutations in BRCA1 or BRCA2 genes: tumor suppressor genes that control cell proliferation. BRCA1 and 2 genes account for proteins that are directly involved in the repair of damaged DNA. The study
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.